ey0018.4-7 | Growth Hormone Therapy: Safety | ESPEYB18
A Tidblad
, M Bottai
, H Kieler
, K Albertsson-Wikland
, L Savendahl
JAMA Pediatr. 2021;175(2):e205199. doi: 10.1001/jamapediatrics.2020.5199. PMID: 33346824This nationwide population-based study assessed the long-term risk of cardiovascular events in patients who had received rhGH therapy during childhood and adolescence. The study cohort comprised 3.408 subjects treated under the GHD, SGA or ISS indications, and 50 036 age-, sex-, and region-base...